N/A N=49 Vaginally Assisted Laparoscopic Hysteropexy Versus Vaginal Hysterectomy
Pelvic Organ Prolapse
Primary: Number of Participants With Recurrence of Pelvic Organ Prolapse — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=70 Surgical Study Comparing 2 Procedures for the Treatment of a Dropped Bladder
Prolapse
Primary: Change in the Stage of Prolapse of the Anterior Vaginal Wall Before and One Year After Surgery
N/A N=47 Radiofrequency and Hybrid Fractional Laser for Vaginal Rejuvenation
Vaginal Atrophy
Primary: Vulvovaginal Symptoms Questionnaire — 8; 7.88; 5.93; 5.93 score on a scale
N/A N=70 Hysterectomy by Transabdominal Laparoscopy or NOTES
Uterine Diseases
Primary: Successful Removal of the Uterus Without Conversion to Another Technique — 35; 35 Participants — p=0.0221
N/A N=10 Evaluation of the Use of the Renuvion APR System in the Labia
Labia Enlarged · Labium; Hypertrophy
Primary: Evaluation of Change Between Baseline and Follow-up Images as Determined by a Masked, Qualitative Assessment of Photographs at 90-days and 180-days Post-treatment…
Phase 4 N=199 Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen
Pelvic Organ Prolapse · Urogenital Prolapse · Vaginal Vault Prolapse
Primary: Surgical "Failure" Defined by (i) Anatomic Assessment of Prolapse, (ii) Presence of Bulge Symptoms, and/or (Iii) Retreatment of Prolapse — 18; 8 Participants
Phase 2 N=337 Outcomes Following Vaginal Prolapse Repair and Mid Urethral Sling Trial
Pelvic Organ Prolapse
Primary: Number of Participants With Treatment Failure Defined as Subsequent Treatment for Urinary Incontinence, Signs or Symptoms of Bothersome Urinary Incontinence — 39; 85…
Phase 4 N=30 Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor
Pelvic Organ Prolapse · Menopause
Primary: Vaginal Wall Composition: Epithelium (Intention to Treat) — 413.9; 314.1 microns — p=0.21
N/A N=7 A Trial to Evaluate Natural Orifice Transvaginal Endoscopic Cholecystectomy With Laparoscopic Assistance
Gallbladder Disease
Primary: Procedure Completion — 7 participants
N/A N=20 RF Rejuvenation for Pelvic Floor and Vagina
Symptoms Associated With Pelvic Floor Weakness
Primary: Effect of RF on Pelvic Floor Measured by Intentional Muscle Contraction Using Biofeedback EMS — 13.13 mV
N/A N=97 Laparoscopic Enclosed Morcellation; Electromechanic Morcellation vs Vaginal Removal
Myoma
Primary: Operation Time — 146.1; 124.6 seconds
Phase 4 N=64 Barbed Suture vs Smooth Suture for Vaginal Cuff Closure
Closure of Vaginal Cuff at Laparoscopic Hysterectomy
Primary: Vaginal Cuff Closure Time — 10.4; 9.6 minutes
N/A N=54 Postoperative Virtual Clinical Encounters
Pelvic Organ Prolapse
Primary: Patient Satisfaction Via the Patient Satisfaction Questionnaire -18 — 80.7; 81.2 score on a scale
Phase 2 N=75 Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery
Pelvic Organ Prolapse · Surgery · Postoperative Pain
Primary: Primary Postoperative Pain Measured by the Numerical Rating Scale (NRS) — 3.0; 4.0; 3.75 score on a scale — p=0.39
Phase 3 N=302 The Vaginal Health Trial
Atrophy of Vagina · Menopause · Dyspareunia (Female)
Primary: Most Bothersome Symptom (MBS) Severity — -1.2; -1.0; -0.2; -1.4 units on a scale — p=0.25
N/A N=120 Vaginal Cuff Dehiscence and Thermal Injury During TLH
Vaginal Cuff Dehiscence · Thermal Injury
Primary: Degree of Thermal Injury at the Time of Laparoscopic Hysterectomy — 0.68; 0.63; 0.66; 0.70 mm
Phase 1 N=31 Botox Injection for Treatment of Vaginismus
Vaginismus
Primary: Ability to Achieve Pain Free Intercourse. — 90.3 percentage of participants
N/A N=100 Laser Therapy for Treatment of Urogenital Symptoms in Women
Genitourinary System; Disorder, Female · Burning Vagina · Dyspareunia
Primary: Patient Global Impression of Improvement (PGI-I) Score at 4 Weeks After Initial Treatment — 2.66 score on a scale
N/A N=272 Smartmesh Technology in Pelvic Floor Repair Procedures
Pelvic Organ Prolapse
Primary: Number of Patients With a Composite Outcome : Bladder Wound, Rectum Wound, Abnormal Bleeding — 6 Participants
Phase 4 N=107 Preoperative Gabapentin vs Placebo for Vaginal Prolapse Surgery
Pelvic Organ Prolapse · Perioperative/Postoperative Complications
Primary: Postoperative Opioid Use — 25; 20 MMEs
N/A N=190 Performance of Tension Free Vaginal Mesh (Prolift) Versus Conventional Vaginal Prolapse Surgery in Recurrent Prolapse.
Pelvic Organ Prolapse
Primary: Prolapse by "Pelvic Organ Prolapse Quantification System" (POP-Q), at 12 Months — 8; 38; 75; 46 participants — p=<0.05
N/A N=183 Study of Uterine Prolapse Procedures - Randomized Trial
Uterovaginal Prolapse
Primary: Cumulative Failure — 78; 69; 9; 16 Participants
N/A N=713 Xenform Postmarket Surveillance Study
Pelvic Organ Prolapse
Primary: Number of Participants With Success at 36 Months — 191; 390 Participants
Phase 3 N=655 Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence
Urinary Incontinence
Primary: 24 Month Cumulative Success Rate Computed From Kaplan Meier Time-to-event Analysis (Reported as Percent Success). — 38; 47 % success at 24 months — p=0.01
Phase 4 N=76 Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair
Cystocele · Uterine Prolapse · Urinary Incontinence
Primary: Recurrent Stage II or Greater Anterior Vaginal Prolapse — 24; 11 participants — p=0.005
Phase 4 N=44 Pudendal Enhancement of Enhanced Recovery After Surgery (ERAS) for Reconstructive Surgery (PEERS)
Pain Management
Primary: Narcotic Use — 8; 6.75 MME
N/A N=69 Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy
Atrophic Vaginitis · Menopause
Primary: Vaginal Dryness — -5.48; -5.76 units on a scale
N/A N=32 Injection of Botox in the Perineal Muscles in Resistant Cases of Vaginal Spasm
Vaginismus
Primary: Success of Repeated Penetration of the Penis Through the Vaginal Introitus Into the Vagina Without or With Acceptable Pain — 28 participants
N/A N=30 Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal Atrophy
Vulvovaginal Atrophy
Primary: The Main Outcome of the Study is the Efficacy of the Laser Procedure, Intended as the Amelioration of 50% of the Severity of the Vaginal Dryness at 12 Months, Compared…
N/A N=710 Uphold LITE Post-Market Surveillance Study
Pelvic Organ Prolapse
Primary: Primary Efficacy Endpoint - Number of Participants With Composite Anatomic and Symptomatic Success at 36 Months — 201; 389; 199; 384 Participants — p=0.056